welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Capricor trial failure in heart disease might offer another opportunity

On Friday Capricor Therapeutics announced that it had failed a mid-stage trial using its cell therapy treatment on patients with heart attacks. The company suffered a huge setback and the stock tanked 62% on the failed results.

The phase 2 trial that Caprictor Therapeutics ran was known as the ALLSTAR trial. It recruited a total of 142 patients that had experienced a major heart attack with residual cardiac function. The company stated that the trial had demonstrated a low probability of achieving the primary endpoint. Which is the reason why the shares crashed the way they did on Friday. The primary endpoint was to see a statistical significance over a 12-month period change percentage from baseline using an MRI.

Capricor Trial Failure In Heart Disease Might Offer Another Opportunity